Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTQX1G)

• Drug Name: Batimistat Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DMTQX1G

Molecule-Related Drug Atlas

Drug(s) Targeting TNF alpha converting enzyme (ADAM17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apratastat	DM8W4N9	Rheumatoid arthritis	FA20	Phase 2	[2]
Aderbasib	DMYOMSC	Breast cancer	2C60-2C65	Phase 1/2	[3]
GW-3333	DM3PMAZ	Chronic obstructive pulmonary disease	CA22	Preclinical	[4]
DPC-333	DM4JBQD	Inflammatory bowel disease	DD72	Terminated	[4]
IK-862	DMJA4UE	Discovery agent	N.A.	Investigative	[5]
SR-973	DMU48OD	Discovery agent	N.A.	Investigative	[6]
SL422	DM3I2US	Discovery agent	N.A.	Investigative	[7]
PKF-242-484	DMNDLAS	Discovery agent	N.A.	Investigative	[8]
N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide	DMWXUCT	Discovery agent	N.A.	Investigative	[9]
N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl)	DMA6EPH	Discovery agent	N.A.	Investigative	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TNF alpha converting enzyme (ADAM17)	TT6AZXG	ADA17_HUMAN	Inhibitor	[1]

References

• [1] The secretases that cleave angiotensin converting enzyme and the amyloid precursor protein are distinct from tumour necrosis factor-alpha convertase. FEBS Lett. 1998 Jul 10;431(1):63-5.
• [2] Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
• [3] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [4] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [5] Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem. 2008 Oct 1;16(19):8781-94.
• [6] Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.
• [7] Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60.
• [8] Current perspective of TACE inhibitors: a review. Bioorg Med Chem. 2009 Jan 15;17(2):444-59.
• [9] Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5.